Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Non-cash Items (2020 - 2025)

RxSight (RXST) has disclosed Non-cash Items for 6 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 18.67% year-over-year to $17.8 million, compared with a TTM value of $17.8 million through Dec 2025, up 18.67%, and an annual FY2025 reading of $17.8 million, up 18.67% over the prior year.
  • Non-cash Items was $17.8 million for Q4 2025 at RxSight, down from $21.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $24.2 million in Q2 2025 and bottomed at $3.6 million in Q1 2024.
  • Average Non-cash Items over 5 years is $12.9 million, with a median of $10.9 million recorded in 2023.
  • The sharpest move saw Non-cash Items tumbled 66.83% in 2024, then skyrocketed 567.78% in 2025.
  • Year by year, Non-cash Items stood at $8.8 million in 2021, then plummeted by 30.68% to $6.1 million in 2022, then surged by 36.07% to $8.3 million in 2023, then surged by 80.72% to $15.0 million in 2024, then rose by 18.67% to $17.8 million in 2025.
  • Business Quant data shows Non-cash Items for RXST at $17.8 million in Q4 2025, $21.0 million in Q3 2025, and $24.2 million in Q2 2025.